Immunohistochemical analysis of IMP3 and p53 expression in endoscopic ultrasound-guided fine needle aspiration and resected specimens of pancreatic diseases

Senoo, Junichi; Mikata, Rintaro; Kishimoto, Takashi; Hayashi, Masahiro; Kusakabe, Yuko; Yasui, Shin; Yamato, Mutsumi; Ohyama, Hiroshi; Sugiyama, Harutoshi; Tsuyuguchi, Toshio; Yoshitomi, Hideyuki; Ohtsuka, Masayuki; Maeda, Juri; Ota, Satoshi; Nakatani, Yukio; Kato, Naoya

doi:10.1016/j.pan.2017.12.010

Cited by 23 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IMP3 has been reported as a useful diagnostic marker of PDAC for the analysis of core needle biopsy samples or cytological samples 16 , 22 . We recently retrospectively reported that IMP3 was a valuable marker to distinguish malignant from benign lesions for pancreatic solid masses in samples obtained by EUS–FNA as well as surgical samples 13 . In these studies, IMP3 was reported to be diffusely expressed in the entire tumor; therefore, it was useful for analyzing small specimens obtained by EUS–FNA.…”

Section: Discussionmentioning

confidence: 99%

“…The sample size was determined as described in our previous study 13 . An 80% accurate diagnosis was confirmed by histocytological analysis and 90% was confirmed by histocytological plus immunohistological analyses.…”

Section: Methodsmentioning

confidence: 99%

“…Recently, we retrospectively reported that insulin-like growth factor-II messenger ribonucleic acid-binding protein 3 (IMP3) is a valuable marker to distinguish malignant from benign lesions in pancreatic solid masses 13 . IMP3 is an oncofetal protein that is expressed during embryogenesis and is almost silenced in normal mature tissues.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic value of IMP3 and p53 immunohistochemical staining in EUS-guided fine-needle aspiration for solid pancreatic tumors

Mikata

Yasui

Kishimoto

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

We previously identified insulin-like growth factor-II messenger ribonucleic acid-binding protein 3 (IMP3) as a valuable marker to distinguish malignant from benign lesions in pancreatic solid masses. The aim of this prospective study was to evaluate the usefulness of IMP3 and p53 immunohistochemical staining in endoscopic ultrasound-guided fine-needle aspiration (EUS–FNA) samples for pancreatic solid masses. The study recruited 90 consecutive patients with pancreatic masses, including 62 pancreatic ductal adenocarcinomas (PDACs), 11 benign tumors, and 17 other tumors, who underwent EUS–FNA, and conducted IMP3 and p53 immunohistochemical staining. The main outcome measurement was improved diagnostic utility using IMP3 and p53 immunohistochemical staining. IMP3 and p53 expressions were detected in 60.8% and 49.4% of malignant lesions, 69.4% and 58.1% of PDACs, and 0% of benign lesions, respectively. In PDAC and benign tumors, the use of IMP3 and/or p53 immunostaining increased the sensitivity of cytohistological analysis from 88.7 to 93.5%, although the difference was not statistically significant. The sensitivity of histological analysis combined with that of IMP3 staining was 91.9%, which was significantly greater than that of histology alone (80.6%). The use of IMP3 and p53 immunohistochemical staining did not significantly improve the sensitivity of cytohistological analysis; however, IMP3 staining may be helpful for the histological analysis of malignant pancreatic tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic value of IMP3 and p53 immunohistochemical staining in EUS-guided fine-needle aspiration for solid pancreatic tumors

Mikata

Yasui

Kishimoto

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Early efforts focused on immunostaining of a number of proteins, including IMP3, S100, p53, and MIB-1, and have yielded varied results. 19,20 Imaging adjuncts to EUS have also been investigated. Elastography is an ultrasound modality that measures tissue stiffness.…”

Section: Discussionmentioning

confidence: 99%

Protein Signatures and Tissue Diagnosis of Pancreatic Cancer

Underwood

Gerber

Nguyen

et al. 2020

Journal of the American College of Surgeons

View full text Add to dashboard Cite

BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration fails to diagnose up to 25% of patients with pancreatic ductal adenocarcinoma (PDAC). Proteomics can help to overcome this clinical dilemma. We hypothesized that soluble protein signatures can differentiate PDAC from benign tissues. STUDY DESIGN: Tissues were obtained from resected surgical specimens, lysed, and homogenates collected for analysis with a 41-protein multiplex assay. Analyte concentrations were normalized to total protein. Statistical analysis was performed to evaluate for differences in PDAC vs benign tissue. RESULTS: Tissues were obtained from 159 patients, 82 patients with PDAC naïve to therapy and 77 with benign pancreatic pathology. Fourteen analytes had a receiver operating characteristic curve area of >0.75 for predicting PDAC vs benign tissue. A recursive partitioning model using only 2 analytes, interleukin 1 receptor antagonist and transforming growth factor-a, provided an accuracy, sensitivity, and specificity of 91.2%, 90.2%, and 92.2%, respectively. A penalized logistic regression model found 12 analytes that provide diagnostic value to a protein signature. The mean area under the receiver operating characteristic after 50 tenfold cross-validations was 0.951. Accuracy, sensitivity, and specificity of this model were 91.2%, 87.8%, and 94.8%, respectively. Applying the scenario of 80% disease prevalence in patients undergoing endoscopic ultrasound with fine-needle aspiration for a pancreatic head mass, positive predictive value is 98.5% (95% CI 93.0% to 99.7%) and negative predictive value is 66.0% (95% CI 54.9% to 75.6%). CONCLUSIONS: Protein signatures from pancreatic specimens can differentiate PDAC from benign tissue. Additional work to validate these findings in a unique sample set is warranted.

show abstract

“…Wei et al (35) detected high IMP3 expression in colorectal carcinomas and low expression in colorectal adenomas. Moreover, Senoo et al (36) found that IMP3 expression was higher in malignant intraductal papillary mucinous neoplasms than in their benign counterparts. Also, Kanzaki et al (37) reported positive IMP3 expression in cutaneous SCC, whereas there was no IMP3 expression in keratoacanthoma.…”

Section: Discussionmentioning

confidence: 99%

IMMUNOHISTOCHEMICAL VALIDATION OF INSULIN-LIKE GROWTH FACTOR II mRNA-BINDING PROTEIN 3 (IMP3) AS A DIAGNOSTIC MARKER IN SALIVARY GLAND TUMORS

Madawi

Sheikh

Riad

et al. 2020

Alexandria Dental Journal

View full text Add to dashboard Cite

INTRODUCTION: Salivary gland tumors (SGTs) are infrequent tumours accounting for 2-6.5% of all head and neck tumors. They show various clinical behaviours and different histological patterns resulting in a diagnostic dilemma. Insulin like growth factor II mRNA binding protein 3 (IMP3) is an oncofetal protein that plays an important role in tumor invasion and metastases. Several studies proved the prognostic role of IMP3 in different human cancers. However, its role in SGTs still needs to be confirmed. OBJECTIVES: To evaluate IMP3 immunoexpression in benign and malignant SGTs. MATERIALS AND METHODS: IMP3 expression was measured in 44 SGT cases (20 benign and 24 malignant) and 10 normal salivary gland tissues (NSGT). Immunohistochemical (IHC) staining was carried out by the Labeled Strept-Avidin Biotin complex method (LSAB). RESULTS: IMP3 expression was detected in NSGT as well as benign and malignant SGTs with different intensities. The Lowest expression levels were detected in NSGT, while the highest ones were detected in Malignant SGTs. CONCLUSION: IMP3 could be used as a diagnostic marker in SGTs.

show abstract

Immunohistochemical analysis of IMP3 and p53 expression in endoscopic ultrasound-guided fine needle aspiration and resected specimens of pancreatic diseases

Cited by 23 publications

References 33 publications

Diagnostic value of IMP3 and p53 immunohistochemical staining in EUS-guided fine-needle aspiration for solid pancreatic tumors

Diagnostic value of IMP3 and p53 immunohistochemical staining in EUS-guided fine-needle aspiration for solid pancreatic tumors

Protein Signatures and Tissue Diagnosis of Pancreatic Cancer

IMMUNOHISTOCHEMICAL VALIDATION OF INSULIN-LIKE GROWTH FACTOR II mRNA-BINDING PROTEIN 3 (IMP3) AS A DIAGNOSTIC MARKER IN SALIVARY GLAND TUMORS

Contact Info

Product

Resources

About